tbuckley/cabot-search huggingface dataset:
Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
Authors: Daniel Keizman, Maya Ish-Shalom, Natalie Maimon, Maya Gottfried, Roberto Pili, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Ben Boursi, Rony Weitzen, Henry Hayat, Avivit Peer, Avivit Neumann, Svetlana Kovel, Avishay Sella, Wilmosh Mermershtain, Keren Roubinov, Raanan Berger, Michael Anthony Carducci
Journal: Journal of Clinical Oncology (2013)

458 Background: Geographic differences in the outcome of pts have been described in various cancers. The VEGFR inhibitor su is a standard treatment (tx) for mRCC. The effect of geographic differences on the outcome of su tx in mRCC is poorly defined. We aimed to study the effect of geographic differences on outcome of su tx in mRCC. Methods: We performed an international multicenter retrospective study of unselected cohort of 275 mRCC pts, who were treated with su from 2004 to 2012 in 7 centers across the United States and Middle East (ME; Israel). Clinicopathologic and prognostic factors, and tx outcome were compared between United States (n=133) and ME (n=142) pts. Chi-square and Fisher's exact tests were used to compare categorical variables, and two-sample t-test was used to compare continuous endpoints. Progression free survival (PFS) and overall survival (OS) were determined by Cox regression. Results: Median age was 61 (United States) vs. 65 (ME, p = 0.01). The groups were balanced regarding gender, Heng risk, past nephrectomy, RCC histology, presence of ≥ 2 metastatic sites, lung/liver/bone metastasis, use of angiotensin system inhibitors (ASI), prior cytokines/ targeted txt, su induced HTN, and su dose reduction/tx interruption secondary to side effects. The incidence of active smokers (28% vs. 15%, p =0.01), bisphosphonates users (23% vs. 13%, p = 0.03) and pts with pre-tx neutrophil to lymphocyte ratio (NLR) ≤ 3 (63% vs. 49%, p = 0.04) was higher among ME pts. In United States vs. ME pts, objective response was partial response/stable disease 77% (n=102) vs. 79% (n=112), and progressive disease at first imaging evaluation within the first 3 months (mos) 23% (n=31) vs. 21% (n=30) (p = 0.77, OR 1.1). Median PFS was 8 vs. 12 mos (HR=1.8, p &lt; 0.0001), and median OS 21 vs. 22 mos (HR=0.94, p = 0.9) in United States vs ME pts. Factors associated with PFS in multivariate analysis of the entire cohort (n=275) were geographic location (United States vs. ME), Heng risk, RCC histology, su induced HTN, ASI use, pre-tx NLR, and smoking status. Conclusions: Geographic differences in clinicopathologic factors and PFS of pts with mRCC treated with su may exist. This should be further investigated, and if validated, applied in clinical practice and clinical trials.
Reversing vasectomy.
Authors: D. N. Tulloch
Journal: BMJ (1992)

drugs.A prostaglandin E1 analogue reverses the deleterious effect of giving corticosteroid, as we previously showed for indomethacin.Piper et al concluded that their study might have missed an effect of corticosteroids alone on peptic ulcer disease as less than 8% of the patients they studied were taking doses of over 30 mg/day.Though we do not yet have data from humans, particularly on the rate of regenerative repair of peptic ulcers during treatment with corticosteroid, we do not believe that a clinically relevant effect of these drugs on human peptic ulcer disease in the absence of concomitant non-steroidal anti- inflammatory treatment has yet been ruled out.On this, as on the potential protective effects of prostaglandins and acid reducing agents, insufficient data are available.
Collagen disease in children. A review of 71 cases
Authors: W. P. Coleman
Journal: JAMA (1977)

Seventy-one children with the diagnosis of systemic lupus erythematosus (SLE) (39 cases), dermatomyositis (25 cases), or scleroderma (7 cases) were studied retrospectively. The children with SLE were much sicker than those with the other two diseases and were found to have a poorer prognosis than adults with SLE. In general, the earlier the age of onset, the poorer the prognosis. Early gastrointestinal bleeding, abnormal renal findings, and cardiac abnormalities heralded early death from SLE. The peak incidence of SLE near the time of puberty suggests hormonal influence on this disorder in children. Survival rates and morbidity improved as the treatment improved. Corticosteroids were the main therapeutic agents. The patients with scleroderma also received varying doses of vitamin E, penicillamine, chloroquine hydrochloride, and salicylates. The antimetabolites were used to treat SLE starting in the late 1960s. (<i>JAMA</i>237:1095-1100, 1977)
Permission Information Line Omitted.
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obituary: E. A. THOMSON, M.B., Ch.B
Journal: BMJ (1958)

OBITUARY BRff=MEDICAL JOURNA!, and he touched people graciously as well as things.A game of golf with him was a delightful experience and some- thing to live over again in one's memory for the sheer fun of recalling the incidents he contributed to the game as such a doughty and courteous opponent.It is no wonder that to-day a countless number of colleagues and former students are remembering "Jim " Brash with pride, affection, and gratitude, and find in what they remember of his friendship and example fresh inspiration and courage to play their part more worthily in the battle of life.Their sincere sympathy goes out to the gracious lady whose devoted service and support meant so much to her husband in everything he did and undertook, and also to the son and daughter who so worthily carry on.
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
Authors: May Thet Cho, Dean Lim, Timothy W. Synold, Paul Henry Frankel, Lucille A. Leong, Joseph Chao, Vincent M. Chung, Yuan Chen, Stephen Sentovich, Eloise Luevanos, Marwan Fakih
Journal: Journal of Clinical Oncology (2016)

2544 Background: Pre-clinical studies have shown that the combination of MEK inhibitors and 5-FU improves antitumor activity and that MEK inhibition overcomes both 5FU and platinum resistance. This phase I study was to determine the maximum tolerated dose (MTD) of the combination MEK162 and FOLFOX. Methods: Patients (pts) with metastatic colorectal cancer (mCRC) who progressed or failed prior 5FU, irinotecan, oxaliplatin and/or anti-EGFR therapy received twice daily MEK162 continuously or intermittently in combination with every-2-week FOLFOX without bolus 5-FU. Two dose levels of MEK162 (30mg and 45mg) were investigated in a standard 3 + 3 escalation design. Limited pharmacokinetic (PK) analysis of 5FU and oxaliplatin was performed at the MTD. An additional 6-patient expansion cohort of MEK162, a the defined MTD, was given BID on D1-D5 followed by FOLFOX on Day 6, repeated every 2 weeks. Dose limiting toxicity (DLT) was defined as any treatment-related grade (G) 3 or 4 non-hematological toxicity (with the exception of G3 diarrhea or vomiting < 48 hrs) or G 4 neutropenia or thrombocytopenia within the first 2 cycles (4 weeks) of the treatment. Results: 16 pts were enrolled in the continuous MEK162 arm (median age (range) 53 yrs (49-78); 11 men; ECOG 0/1 in 9/7 patients). No DLT was noted on the study. The MTD of MEK162 was 45 mg PO BID. An additional 6 pts (for a total of 12) were enrolled at the MTD for PK analysis and none of them developed DLT defining toxicities. A median of 8 cycles (range 1-19) was administered. Treatment-related ≥ grade 3 toxicities included anaphylaxis due to oxaliplatin (n = 1), CPK elevation (n = 2), neutropenia (n = 1), peripheral neuropathy (n = 3), thrombocytopenia (n = 1), retinal vascular disorder (n = 1), and acneiform rash (n = 1). 10 pts had SD at 2 months (m) by radiographic assessment, 5 of whom with stabilizations of > 4 m (4-10 m). There were no significant differences in either 5-FU or oxaliplatin PK's with or without MEK162. None of the intermittent MEK162 pts developed a DLT and all 6 progressed at 2 m. Conclusions: The combination of continuous MEK162 and FOLFOX has a manageable toxicity profile and promising antitumor activity in heavily pretreated mCRC patients. Clinical trial information: NCT02041481.
THE INCREASED PREDISPOSITION TO CANCER.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.
Authors: H Bouharoun-Tayoun, C Oeuvray, F Lunel, P Druilhe
Journal: The Journal of Experimental Medicine (1995)

The relevance of the antibody-dependent cellular inhibition (ADCI) of Plasmodium falciparum to clinical protection has been previously established by in vitro studies of material obtained during passive transfer of protection by immunoglobulin G in humans. We here report further in vitro investigations aimed at elucidating the mechanisms underlying this ADCI effect. Results obtained so far suggest that (a) merozoite uptake by monocytes (MN) as well as by polymorphonuclear cells has little influence on the course of parasitemia; (b) the ADCI effect is mediated by a soluble factor released by MN; (c) this or these factors are able to block the division of surrounding intraerythrocytic parasites at the one nucleus stage; (d) the critical triggering antigen(s) targeted by effective Abs would appear to be associated with the surface of merozoites, as opposed to that of infected red blood cells; (e) the MN receptor for Abs effective in ADCI is apparently Fc gamma RII, and not RI; (f) MN function is up- and down-regulated by interferon-gamma and interleukin 4, respectively; and (g) of several potential mediators released by MN, only tumor necrosis factor (TNF) proved of relevance. The involvement of TNF in defense may explain the recently described increased frequency of the TNF-2 high-expression promoter in individuals living in endemic regions despite its compromising role in severe malaria.
Impaired arginine-vasopressin secretion associated with hypoangiotensinemia in hypernatremic dehydrated elderly patients
Authors: T. Yamamoto
Journal: JAMA (1988)

Nine elderly patients, some with preceding dementia, presented with adipsia, progressive dehydration, impaired consciousness, and hypernatremia following common acute infections without gastrointestinal disturbance. Studies before rehydration revealed inappropriately low plasma arginine-vasopressin (AVP) levels for plasma osmolality, insufficiently concentrated urine, absolutely or relatively low plasma angiotensin II (A-II) concentrations (compared with plasma renin activity and plasma angiotensin I concentrations), and low serum angiotensin I—converting enzyme activities. The plasma AVP concentrations were positively correlated with the plasma A-II concentrations (<i>r</i>=.677) but not with plasma osmolality. The plasma AVP level was raised by an intravenous infusion of A-II in one patient. These findings suggest the following sequence of events: impaired A-II production caused impairment of thirst perception, renal-concentrating capacity, and AVP secretion and contributed to development of hypernatremic dehydration in these elderly patients. (<i>JAMA</i>1988;259:1039-1042)
Intravenous Metoclopramide
Authors: Stephen B. Strum
Journal: JAMA (1982)

An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting. Thirty-eight patients received a total of 83 assessable courses of chemotherapy with cisplatin alone or in combination with other cytotoxic agents. In 19 of 38 patients (50%) or 40 of 83 courses (48%, nausea or vomiting did not occur ("total protection") and in six of 38 patients (16%) or 19 of 83 courses (23%), emesis occurred one or two times ("major protection"). Thus, 25 of 38 patients (66%) receiving 59 of 83 courses (71%) of cisplatin-containing chemotherapy attained either total or major antiemetic protection with metoclopramide. In those patients who received multiple courses of chemotherapy, antiemetic protection afforded by metoclopramide remained unabated. At this dosage, the drug was well tolerated with minimal side effects. Intravenous metoclopramide is consistently effective in preventing emesis associated with cisplatin when used either alone or in combination with other cancer chemotherapy agents that are in themselves emetogenic. (<i>JAMA</i>1982;247:2683-2686)
Immune System Boosters Set for FDA Go-Ahead
Authors: Charles Marwick
Journal: JAMA (1991)

GENETICALLY engineered immune system modulators are entering the mainstream of medical practice. An advisory committee to the Food and Drug Administration (FDA) has recommended that the commissioner license two of these agents. One is granulocyte macrophage colony-stimulating factor (GM-CSF) and the other is granulocyte colony-stimulating factor (G-CSF) (<i>JAMA</i>. 1990; 264:1233). Both are immune system boosters. Their main role is the mitigation of infections in cancer patients. The agents increase the neutrophils that are killed by the chemotherapy these patients receive as treatment for their disease. <h3>Marrow, Lymphoma, Leukemia</h3> The first agent has been shown to be effective in stimulating engraftment of bone marrow transplants and in reducing infections in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia. The GM-CSF is classified as an orphan drug and is currently available to patients under the treatment investigational new drug system. Of the approximately 40 000 cases of non-Hodgkin's lymphoma that occur annually,
AUTOANTIBODIES AND RHEUMATOID ARTHRITIS
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correlation between biochemical indicators of lead exposure and semen quality in a lead-poisoned firearms instructor
Authors: J. Fisher-Fischbein
Journal: JAMA (1987)

LEAD poisoning is a disease of great public health concern, particularly because of the hazards that lead can pose to children as a result of ingestion of lead-based paint and perhaps as a consequence of the effects of lead pollution of the ambient air.<sup>1</sup> However, lead poisoning is also a common occupational disease among adults.<sup>2</sup>Groups at high risk of developing this disorder include smelter workers,<sup>3</sup>workers engaged in flame cutting of lead-painted iron and steel structures,<sup>4</sup>and arts and craft workers. Persons who work as instructors at indoor firing ranges are likewise at high risk for occupational lead poisoning.<sup>5</sup>The typical biochemical features of lead poisoning include inhibition of heme synthesis manifested by elevated levels of erythrocyte protoporphyrin (free erythrocyte protoporphyrin and zinc protoporphyrin [ZPP]) and decreased activity of δ-aminolevulinic acid dehydratase.<sup>6,7</sup>Common symptoms are nonspecific neurologic symptoms (eg, headache, dizziness, fatigue, and sleep
Response to Letters Regarding Article, “Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials”
Authors: Samia Mora, Robert J. Glynn, Jean G. MacFadyen, Paul M. Ridker, Judith Hsia, Jacques Genest
Journal: Circulation (2010)
Poststreptococcal Pustulosis
Authors: Tal Goldberger, Vered Molho-Pessach
Journal: New England Journal of Medicine (2020)

A 47-year-old man presented with a pustular rash that had developed on both hands 1 week after he had received a diagnosis of group A β-hemolytic streptococcus pharyngitis. A diagnosis of poststreptococcal pustulosis was made.
Quality of Care and Satisfaction Among Patients Isolated for Infection Control
Authors: Stephen G Weber, Trish M Perl, Sara E Cosgrove
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pancreatic and lymph node metastases from maxillary osteosarcoma diagnosed by endoscopic ultrasound-guided fine needle aspiration
Authors: J. Araújo, J. Carvalho Junior, G. Monges, F. Bertucci, L. Rossini, M. Giovannini
Journal: Endoscopy (2012)

Correction to: Pancreatic metastasis from osteosarcoma diagnosed by endoscopic ultrasound fine-needle aspiration biopsy (EUS-FNAB)Endoscopy 2012; 44(S 02): E151-E152DOI: 10.1055/s-0031-1291643
HIGHER MEDICAL EDUCATION.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal